Denver, Colorado - Medical device maker and biopharmaceutical company Ceragenix Pharmaceuticals Inc. is to present data indicating that coating catheters with an antimicrobial polyurethane-based layer may be an effective route to preventing infection at the upcoming Medtech Insight conference to be held 28- 29 April 2008 in Paris.
At the conference - "Investment In Innovation (In3) Europe: Bridging European and US Medical Device Innovators, Investors and Companies" - Creagenix will present data from recent testing on its proprietary CeraShield material. These tests compared the in-vitro antimicrobial efficacy against daily doses of E.coli. of CeraShield-coated urinary silicone catheters and commercially available urinary catheters containing either silver or nitrofurazone
Use of urinary catheters is linked to urinary tract infections - which add over $450 million in hospital costs annually in the US, and E.coli is the most common common pathogen associated with such infections, said the company. More than 900 000 Americans who require use of a urinary catheter are estimated to develop a urinary tract infection annually.
According to Steve Porter, chairman and ceo of Ceragenix, "The recent decision by the Center for Medicare Services to no longer reimburse hospitals for hospital-acquired urinary tract infections has generated increased interest in novel technological solutions to help reduce the incidence of such infections."
Polyurethane-based CeraShield contains CSA-13, a Ceragenin compound "that has been shown to have broad-spectrum efficacy against gram-positive and gram-negative pathogens, including multi-drug resistant strains," according to Ceragenix.
The company has recently released data showing that CeraShield-coated endotracheal tubes were effective for 21 days in preventing bacterial colonisation and biofilm formation when challenged with daily high innoculations of Pseudomonas aeruginosa.
Current research indicates that silver-coated urinary catheters reduce the rate of bacteriuria for men using urinary catheters for 5 days or less, but not for longer-term use.
Denver-headquartered Ceragenix believes that CeraShield treatment "may offer significant advantages over existing technological approaches. We look forward to conducting the necessary additional testing to bring this promising technology to market," commented Porter.